There is a quiet, persistent bottleneck in biology. You can sequence a genome cheaply, and you can train an AI model on petabytes of protein data. But actually generating that data, running the physical experiments to test a new drug candidate or enzyme, still happens one painstaking, expensive, milliliter-scale reaction at a time. It’s like trying to map a continent with a single, slow-moving surveyor. Surfacto, a Hamburg-based spin-out of the Max Planck Institute for Medical Research, thinks the surveyor should be an army of millions.
Their method is droplet microfluidics. The concept itself isn’t new. The idea is to use tiny, uniform droplets of liquid, each acting as its own isolated reaction vessel, to run thousands or millions of experiments in parallel. The hard part, as any lab technician who has tried to commercialize the technique will tell you, is making it work reliably outside a PhD candidate’s bespoke setup. Surfacto’s bet is that the missing piece isn’t just the microfluidic chip, but the proprietary chemistry that makes the droplets stable, and the instrument that makes the whole process repeatable. They are selling, in essence, a data-generation engine for biology [PERPLEXITY SONAR PRO BRIEF].
The Wedge: Chemistry Meets Hardware
Surfacto’s system produces microdroplets small enough to encapsulate a single human cell or molecule, creating picolitre-sized environments where biological reactions can occur in isolation [PERPLEXITY SONAR PRO BRIEF]. The company claims this allows experiments to become up to 100,000 times more statistically significant by sheer volume [Innosphere, August 2026]. The commercial wedge is the integration. They are not just selling a chip; they are selling a packaged combination of in-house microfluidic instrumentation and their proprietary surfactant chemistry, which they say stabilizes these minute reaction environments [surfacto.com, retrieved 2026]. This is a classic deep-tech play: take a decade of academic research from the Max Planck Society, productize it into something an R&D team can order and use, and aim it at partners in biotech, research organizations, and the new wave of AI-native biology companies [PERPLEXITY SONAR PRO BRIEF].
The Team from the Lab Bench
The founding team reads like a page from a German research institute’s directory, which is precisely the point.
| Role | Name | Background |
|---|---|---|
| CEO/CTO | Dr. Jacqueline De Lora | Scientist-entrepreneur in droplet biotech; PhD from University of New Mexico; research at Max Planck Institute for Medical Research [Startup City Hamburg, retrieved 2026][Jacqueline De Lora - project-short.com, retrieved 2026]. |
| CBO | Dr. Martin Schröter | Co-founder with a PhD in chemistry from the University of Heidelberg [PERPLEXITY SONAR PRO BRIEF]. |
| COO | Benedikt Eikmanns | Co-founder and senior consultant; doctoral candidate at Technical University of Munich [Forbes, February 2021]. |
The company’s identity as a Max Planck spin-off is its foundational credential, a signal of deep technical provenance in a field where trust in the underlying science is non-negotiable [Max-Planck-Innovation, retrieved 2026].
Early Fuel and the Path to Traction
Surfacto is in the earliest stages of proving its business model. In 2026, it was selected for the first cohort of the iF Momentum deep-tech program, which provided a €100,000 cash contribution structured as a convertible loan [Impossible Founders, October 2026]. This is pre-seed fuel for a capital-intensive hardware-plus-chemistry build. The available public record does not yet name paying biotech customers or detail deployment timelines, which is the critical next proof point. The company states it is partnering with biotech and AI-biology teams, but the nature of those partnerships,pilots, paid contracts, or co-development,remains to be demonstrated [PERPLEXITY SONAR PRO BRIEF].
The Unit Economics of Discovery
The risks here are not subtle. They are the classic hurdles of any deep-tech hardware startup: scaling manufacturing, moving from lab prototypes to robust, user-friendly instruments, and convincing risk-averse biopharma R&D departments to change a fundamental workflow. The value proposition hinges on a dramatic reduction in cost and time per data point. If a traditional screening run costs €10,000 and takes a week, Surfacto’s system would need to deliver that same statistical power for a fraction of the cost and time to justify the switch. The 100,000x significance claim is a headline grabber, but the real metric for customers will be cost per meaningful result and the speed to their next research milestone.
Surfacto’s ultimate competitor isn’t another droplet startup. It’s the entrenched, mundane technology of the microtiter plate,the standard plastic plate with 96 or 384 little wells that has dominated labs for decades. It’s simple, cheap, and everyone knows how to use it. For Surfacto to win, its system must become so reliable and its data so compelling that it makes the plate look like a blunt instrument. That’s a high bar, but it’s the kind of bet that, if it pays off, doesn’t just build a company. It changes how discovery is done.
Sources
- [PERPLEXITY SONAR PRO BRIEF] Surfacto company brief | PERPLEXITY SONAR PRO BRIEF
- [Innosphere, August 2026] Innosphere Expands Innovation Network Across Mountain West | https://www.innosphereventures.org/news/innosphere-expands-innovation-network-across-mountain-west
- [surfacto.com, retrieved 2026] Surfacto, Data-driven biology at unprecedented scale | https://surfacto.com/
- [Startup City Hamburg, retrieved 2026] Startup City Hamburg profile | Startup City Hamburg
- [Jacqueline De Lora - project-short.com, retrieved 2026] Jacqueline De Lora academic background | Jacqueline De Lora - project-short.com
- [Forbes, February 2021] Decentralized Finance Will Change Your Understanding Of Financial Systems (mentions Benedikt Eikmanns) | https://www.forbes.com/sites/philippsandner/2021/02/22/decentralized-finance-will-change-your-understanding-of-financial-systems/?sh=5d9b4eb45b52
- [Max-Planck-Innovation, retrieved 2026] 4Investors Day 2025: Research-based Start-ups Meet Investors in Berlin | https://www.max-planck-innovation.com/max-planck-innovation/news/press-releases/press-release/4investors-day-2025.html
- [Impossible Founders, October 2026] iF Momentum: Deep-Tech Program | https://impossiblefounders.com/momentum